Prostate specific antigen: Biology, biochemistry and available commercial assays

Annals of Clinical Biochemistry

Volumn 38, Issue 6, 2001, Pages 633-651

  Milford Ward, A ^a,b   Catto, J W F ^a,b   Hamdy, F C ^a,b  

^a NORTHERN GENERAL HOSPITAL   (United Kingdom)

^b ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADENOCARCINOMA; BLOOD; BLOOD ANALYSIS; CHEMISTRY; HUMAN; IMMUNOASSAY; IMMUNOLOGY; MALE; METHODOLOGY; PROSTATE; PROSTATE HYPERTROPHY; PROSTATE TUMOR; PROSTATITIS; QUALITY CONTROL; REVIEW; SENSITIVITY AND SPECIFICITY; STANDARD; UNITED KINGDOM;

ADENOCARCINOMA; BLOOD CHEMICAL ANALYSIS; GREAT BRITAIN; HUMAN; IMMUNOASSAY; MALE; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; PROSTATITIS; QUALITY CONTROL; REFERENCE STANDARDS; SENSITIVITY AND SPECIFICITY;

EID: 0035512969     PISSN: 00045632     EISSN: None     Source Type: Journal    
DOI: 10.1258/0004563011901055     Document Type: Review

References (151)

1. Brawer MK, Rennels MA, Nagle RB, Schilman R, Gaines JA. Serum prostate specific antigen and prostate pathology in men having a simple prostatectomy. Am J Clin Pathol 1989; 92: 760-4
2. Hasui Y, Maratsuka K, Asada Y, Ide H, Nishi S, Osada Y. Relationship between serum prostate specific antigen and histological prostatitis in patients with benign prostatic hyperplasia. Prostate 1994; 25: 91-6
3. Dalton DL. Elevated serum prostate specific antigen due to acute bacterial prostatitis. Urology 1989; 33: 465
4. Pansadoro V, Emiliozzi P, Defidio L, Scarpone P, Sabatini G, Brisciani A, et al. Prostate-specific antigen and prostatitis in men under fifty. Eur Urol 1996; 30: 24-7
5. Tchetgen MB, Oesterling JE. The effect of prostatitis, urinary retention, ejaculation and ambulation on serum prostate specific antigen concentration. Urol Clin North Am 1997; 24: 283-6
6. Brunner H, Weidner W, Schiefer H-G. Studies of the role of Ureaplasma urealyticum and Mycoplasma hominis in prostatitis. J Infect Dis 1983; 147: 807-13
7. Crawford ED, Schulz MJ, Clejan S, Drago J, Resnick M, Chodak GW, et al. The effect of digital rectal examination on prostate specific antigen level. JAMA 1993; 267: 2227-8
8. Walz PH, Schoppman TH, Buscher C, Ennen J, Schriewer H. Influence of prostatic disease and prostatic manipulations on the concentration of prostate specific antigen. Eur Urol 1992; 22: 20-6
9. Ahluwalia MS, Tandon HD. Nodular hyperplasia of the prostate in North India: an autopsy study. J Urol 1965; 93: 94
10. Cockett AT, Khoury S, Aso Y. Proceedings of the 2nd International Consultation on BPH, Channel Islands, UK. Geneva: Scientific Communication International Ltd. 1983
11. Eri LM, Tveler KJ. Alpha blockade in the treatment of symptomatic benign prostatic hyperplasia. J Urol 1995; 154: 923-34
12. Vaughan ED, Lepor H. Medical management of BPH: part I. Am Urol Assoc Update Series 1996; 16: 18-24
13. Slamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E. Prostate specific antigen as a serum marker for adenocarcinoma of the prostate. New Engl J Med 1987; 317: 909-16
14. Office for National Statistics. Mortality Statistics. DH2 [22]. London: The Stationery Office, 1995
15. Chamberlain J, Melia J, Moss S, Brown J. Report prepared for the health technology assessment panel of the NHS executive on the diagnosis, management, treatment and costs of prostate cancer in England and Wales. Brit J Urol 1997; Suppl 3: 1-32
16. Scardino PT, Wheeler TM. Local control of prostatic cancer with radiotherapy: frequency and prognostic significance of positive results of postirradiation prostatic biopsy. Natl Cancer Inst Mon 1988; 7: 95-103
17. Murphy M, Johnston C, Whelan P, Rider L, Lloyd SN. Changing trends in prostatic cancer. BJU International 1999; 83: 786-91
18. Stamey TA, Freiha FS, McNeal JE, Redwine EA, Whittemorc AS, Schmid HP. Localized prostate cancer. Relationship of tumour volume to clinical significance for treatment of prostate cancer, association with metastatic levels of prostate specific antigen. Cancer 1993; 71: 933-8
19. Giovannucci E, Rimm EB, Colditz GA, Stampfer MJ, Ascherio A, Chute CC, et al. A prospective study of dietary fat and prostate cancer. J Natl Cancer Inst 1993; 85: 1571-9
20. Pienta KJ, Esper PS. Risk factors for prostate canter. Arch Int Med 1993; 118: 793-803
21. Carter BS, Beaty TH, Steinberg GD, Childs B, Walsh PC. Mendelian inheritance of familial prostate cancer. Proc Natl Acad Sci USA 1992; 89: 3367-71
22. McNeal JE. The prostate and prostatic urethra: a morphological synthesis. J Urol 1972; 107: 1008-16
23. Byar DP. Survival of patients with incidentally found microscopic cancer of the prostate; results of a clinical trial of conservative treatment. J Urol 1972; 108: 908-13
24. Brawer MK, Hagle RB, Bigler SA, Lange PH, Sohlberg OE. Significance of prosmtic intraepithelial neoplasia on prostate needle biopsy. Urology 1991; 38: 103-7
25. Gleason DF, Mellinger GT. The Veterans Administration Cooperation Urological Research Group: Prediction of prognosis for prostatic carcinoma by combined histological grading and clinical staging. J Urol 1974; 111: 58-64
26. Dearnaley DP. Cancer of the prostate. BMJ 1994; 308: 780-4
27. Lange PH. New information about prostate specific antigen and the paradoxes of prostate cancer. JAMA 1995; 273: 336-7
28. Nash AF, Melezinek I. The role of prostate specific antigen measurement in the detection and management of prostate cancer. Endocrine Related Cancer 2000; 7: 37-51
29. Perrotti M, Rabbani F, Farkas A, Ward WS, Cummings KB. Trends in poorly differentiated prostate cancer 1973-1994; observations from the Surveillance, Epidemiology and End Results database. J Urol 1998; 160: 811-5
30. Mettlin CJ, Murphy GP, Ho R, Menck HR. The National Cancer Data Base report on longitudinal observations on prostate cancer. Cancer 1996; 77: 2162-6
31. Skarsgar D, Tonita J. Prostate cancer in Saskatchewan Canada, before and during the PSA era. Cancer Causes Control 2000; 11: 79-88
32. Dennis LK, Resnick ML. Analysis of recent trends in prostate cancer incidence and mortality. Prostate 2000; 42: 247-52
33. Selley S, Donovan J, Faulkner A, Coast J, Gillatt D. Diagnosis, management and screening of early localised prostate cancer. Health Technology Assessment 1997; 1: 1 96
34. Moss SM, Melia J. Screening for prostate cancer: the current position. Brit Med Bull 1998; 54: 791-805
35. Partin AW, Yoo JK, Carter HB, Pearson JD, Chan DW, Epstein JL, et al. The use of prostate-specific antigen, clinical stage and Gleason score to predict pathological stage in men wild localized prostate cancer. J Urol 1993; 150: 110-4
36. Moreno JG, Croce CM, Fischer R, Manne M, Vihko P, Mulholland SG, et al. Detection of haematogenous micrometastasis in patients with prostate cancer. Cancer Res 1992; 52: 6110
37. Walsh PC. Anatomical radical retropubic prostatectomy. In: Walsh PC, et al., eds. Campbells Urology, 7th edn. Philadelphia: WB Saunders Company, 1998: 2865-86
38. Catalona WJ. The management of prostate cancer. New Engl J Med 1994; 331: 996-1004
39. Chodak GW, Thisted RA, Gerber GS, Johansson JE. Adolfsson J, Jones GW. et al. Results of conservative management of clinically localised prostate cancer. New Engl J Med 1994; 330: 242-8
40. Belanger A, van Halheek H, Graves HC, Grandbois K, Stamey TA, Huang L, et al. Molecular mass and carbohydrate structure of prostate specific antigen: studies for establishment of an International PSA standard. Prostate 1995; 27: 187-97
41. Lundwall A, Lilja H. Molecular cloning of human prostate specific antigen cDNA. FEBS Lett 1987; 214: 317-22
42. Zhang W-M, Leinonen J, Kalkkinen N, Dowell B, Stenman U-H. Purification and characterisation of different molecular forms of prostate specific antigen in human seminal fluid. Clin Chem 1995; 41: 1567-73
43. Watt KW, Lee PJ, M'Timkulu T, Chan WP, Loor R. Human prostate specific antigen: structural and functional similarity with serine proteases. Proc Natl Acad Sci USA 1986; 83: 3166-70
44. Reigman PH, Vlietstra RJ, Suurmeijer L, Cleutjens CB, Trapman J. Characterisation of the human kallikrein locus. Genomics 1992; 14: 6-11
45. McCormack RT, Rittenhouse HG, Finlay JA, Sokoloff RL, Wang TJ, Woltert RL, et al. Molecular forms of prostate specific antigen and the human kallikrein gene family: a new era. Urology 1995; 45: 729-44
46. Paus E, Nustad K, Bormer OP. Epitope mapping and affinity estimation of 83 antibodies against prostate specific antigen. Tumour Biol 1999; 20(Suppl 1): 52-9
47. Black MH, Grass CL, Leinonen J, Stenman U-H, Diamandis EP. Characterisation of monoclonal antibodies for prostate specific antigen and development of highly specific free prostate specific antigen assays. Clin Chem 1999; 45: 347-54
48. Wang MC, Papsidero LC, Kuriyama M, Valenzuela LA, Murphy GP, Chu TM. Prostate antigen: a new potential marker for prostatic cancer. Prostate 1981; 2: 89-96
49. Mannello F, Malalesta M, Luchetti F, Papa S, Battistelli S, Gazzanelli G. Immunoreactivity, ultrastructural localisation and transcript expression of prostate specific antigen in human neuroblastoma cell lines. Clin Chem 1999; 45: 78-84
50. Lilja H, Oldbring J, Rannevik G. Laurell C-B. Seminal vesicle-secreted proteins and their reactions during gelation and liquefaction of human semen. J Clin Invest 1987; 80: 281-5
51. Fitchner J, Graves H, Shortliffe LD, Grandbois K, Yemoto C, Freiha FS, et al. Prostate specific antigen releases a kinin-like substance that stimulates smooth muscle contracture. J Urol 1994; 151: 313A
52. Diamandis EP. Prostate specific antigen: a cancer fighter and a valuable messenger? Clin Chem 2000; 46: 896-900
53. Cohen P, Graves HC, Peehl DM, Kamarei M, Giudice LC, Rosenfeld RC. Prostate specific antigen (PSA) is an insulin-like growth factor binding protein-3 protease found in seminal plasma. J Clin Endocrinol Metab 1991; 73: 401-7
54. Pollak M, Beamer W, Zhang JC. Insulin-like growth factors and prostate cancer. Cancer Met Rev 1998; 17: 383-90
55. Killian CS, Corral DA, Kavinsky E, Constantine RI. Mitogenic response of osteoblast cells to prostate specific antigen suggests activation of latent TGF-β and proteolytic modulation of cell adhesion receptors. Biochem Biophys Res Commun 1993;92:940-7
56. Cramer SD, Chen Z, Peehl DM. Prostate specific antigen cleaves parathyroid hormone related protein in the PTH-like domain: inactivation of PTHrP stimulated cAMP accumulation in mouse osteoblasts. J Urol 1996; 156: 526-31
57. Fortier AH, Nelson BJ, Grella DK, Holaday JW. Antiangiogenic activity of prostate specific antigen. J Natl Cancer Inst 1999; 91: 1635-40
58. Pretlow TG, Pretlow TP, Yang B, Kaetzcl CS, Delmoro CM, Kamis SM, et al. Tissue concentrations of prostate specific antigen in prostate carcinoma and benign hyperplasia. Int J Cancer 1991; 49: 645-9
59. Zhang MM, Leinonen J, Kalkkinen N, Stenman U-H. Prostate specific antigen forms a complex with and cleaves α1-protease inhibitor. Prostate 1997; 33: 87-96
60. Chen Z, Komatsu K, Prestigiacomo A, Stamey TA. Addition of purified prostate specific antigen to serum of female subjects: studies in the relative inhibition by α2-macroglobulin and αl-antichymotrypsin. J Urol 1996; 156: 1357-63
61. Christensson A, Laurell CB, Lilja H. Enzymatic activity of prostate specific antigen and its reaction with extracellular protease inhibitors. Eur J Biochem 1990; 194: 755-63
62. Cherrier JP, Tournel C, Michel S, Dalbon C, Jolivet M. Two dimensional electrophoresis of prostate specific antigen in sera from men with prostate cancer and benign prostatic hyperplasia. Electrophoresis 1999; 20: 1075-81
63. Chen Z, Chen H, Stamey TA. Prostate specific antigen in benign prostatic hyperplasia: purification and characterisation. J Urol 1997; 157: 2166-70
64. National Committee for Clinical Laboratory Standards. Primary Reference Preparations used to standardise calibration of the immunochemical assays for serum Prostate Specific Antigen (PSA): Approved Guidelines. NCCLS Document I/LA 19-A. Villanova, PA. USA: NCCLS, 1997
65. Piironen T, Villoutriex BO, Becker C, Hollingsworth K, Vihinen M, Bridon D, et al. Determination and analysis of antigenic epitopes of prostate specific antigen (PSA) and human glandular kallikrein 2 (hK2) using synthetic peptides and computer modeling. Protein Science 1998; 7: 259-69
66. Graves HC. Standardisation of immunoassays for prostate specific antigen a problem of prostate specific antigen complexation or a problem of assay design? Cancer 1993; 72: 3141-3
67. Chan DW. Prostate specific antigen: update 1997. J IFCC 1997; 9: 120-5
68. Graves HC, Wehner N, Stamey TA. Comparison of a polyclonal and monoclonal assay for PSA: need for an international antigen standard. J Urol 1990; 144: 1516-22
69. Zhou AM, Tewari PC, Bluestein BL, Caldwell GW, Larsen FL. Multiple forms of prostate specific antigen in serum: differences in immune recognition by monoclonal and polyclonal assays. Clin Chem 1993; 39: 2483-91
70. Nagasaki H, Watanabe M, Komatsu N, Kaneko T, Dube JY, Kujita T, et al. Epitope analysis of a prostate specific antigen (PSA) C-terminal specific monoclonal antibody and new aspects for the discrepancy between equimolar and skewed PSA assay. Clin Chem 1999; 45: 486-96
71. Jung K, Lein M, Schnorr D, Brux B, Henke W, Loening S. Comparison between equimolar- and skewed-response assays for prostate specific antigen: is there an influence on the clinical significance when measuring total prostate specific antigen? Ann Clin Biochem 1996; 33: 209-14
72. Lee M, Milford Ward A, White PA. Evaluation of the Abbott IMx PSA assay. MDA Evaluation Report. London: The Stationery Office. 1995. MDA 95/86
73. Patel D, Milford Ward A, White PA. Evaluation of the Abbott AxSYM Kree PSA assay. MDA Evaluation Report. London: The Stationery Office, 1999, MDA 99/20
74. Lee M, Milford Ward A, White PA. Evaluation of the Ciba-Corning ACS: 180 PSA assay. MDA Evaluation Report. London: The Stationery Office, 1996, MDA 96/54
75. Lee M, Milford Ward A, White PA. Evaluation of the Bayer Immuno-1 PSA assay. MDA Evaluation Report. London: The Stationery Office. 1997, MDA 97/07
76. Patel D, Milford Ward A, White PA. Evaluation of the Beckman-Coulter ACCESS Hybritech PSA assay. MDA Evaluation Report. London: The Stationery Office, 2000. MDA2000/85
77. Lee M, Millbrd Ward A, White PA. Evaluation of the Biodata Biochem Immunosystems MAIAclone PSA assay. MIDA Evaluation Report. London: The Stationery Office, 1996, MDA 96/34
78. Patel D, Milford Ward A, White PA. Evaluation of the BYK-Sangtec LIAISON Free PSA assay. MDA Evaluation Report. London: The Stationery Office, 1999, MDA 99/18
79. Lee M, Milford Ward A, White PA. Evaluation of the BYK-Sangtec LIA-mal PSA assay. MDA Evaluation Report. London: The Stationery Office. 1996, MDA 96/02
80. Patel D, Milford Ward A, While PA. Evaluation of the CanAg Free PSA assay. MDA Evaluation Report. London: The Stationery Office, 1999, MDA 99/38
81. Lee M, Milford Ward A, White PA. Evaluation of the CIS ELSA-2 PSA kit. MDA Evaluation Report. London: The Stationery Office. 1996, MDA 96/53
82. Patel D, Milford Ward A, White PA. Evaluation of the CIS KRYPTOR Free PSA assay. MDA Evaluation Report. London: The Stationery Office. 1999, MDA 99/21
83. Lee M, Milford Ward A, White PA. Evaluation of the DPC Immulite PSA assay. MDA Evaluation Report. London: The Stationery Office, 1995, MDA 95/82
84. Patel D, Milford Ward A, While PA. Evaluation of the DPC Immulite Free PSA assay. MDA Evaluation Report. London: The Stationery Office, 1999. MDA 99/22
85. Lee M, Milford Ward A, White PA. Evaluation of the DPC IRMAcount PSA assay. MDA Evaluation Report. London: The Stationery Office, 1996. MDA 96/68
86. Lee M, Milford Ward A, White PA. Evaluation of the DPC Milenia PSA assay. MDA Evaluation Report. London: The Stationery Office, 1996, MDA 96/67
87. Lee M, Milford Ward A, White PA. Evaluation of the Hybritech TANDEM-E PSA kit. MDA Evaluation Report. London: The Stationery Office, 1996, MDA 96/19
88. Lee M, Milford Ward A, White PA. Evaluation of the Hybritech TANDEM-R PSA kit. MDA Evaluation Report. London: The Stationery Office, 1995, MDA 95/75
89. Lee M, Milford Ward A, White PA. Evaluation of the Roche COBAScorc PSA EIA. MDA Evaluation Report. London: The Stationery Office, 1996, MDA 96/11
90. Lee M, Milford Ward A, White PA. Evaluation of the Boehringer Mannheim ENZYMUN-test PSA kit. MDA Evaluation Report. London: The Stationery Office, 1997, MDA 97/26
91. Patel D, Milford Ward A, White PA. Evaluation of the Roche Elecsys Free PSA assay. MDA Evaluation Report. London: The Stationery Office, 1999, MDA 99/19
92. Lee M, Milford Ward A, White PA. Evaluation of the Wallac DELFIA PROSTATUS PSA EQM kit. MDA Evaluation Report. London: The Stationery Office, 1996, MDA 96/45
93. Lee M, Milford Ward A, White PA. Evaluation of the Wallac DELFIA PROSTATUS PSA Free/Total kit. MDA Evaluation Report. London: The Stationery Office, 1996, MDA 96/46
94. Semjonow A, Oherpenning E, Brandt B. Impact of free-PSA on discordant results of assays for total prostate specific antigen. Urology 1996; 48: 10-15
95. Fox MP, Reilly AA, Schneider E. Effect of the ratio of free to total prostate specific antigen in interassay variability in proficiency testing samples. Clin Chem 1999; 45: 1181-9
96. Zuchelli GC, Pilo A, Chiesa MR, Cohen R, Bizollon CA. Analytical performance of free-PSA immunoassays: results from an inter-laboratory survey. Clin Chem 1997; 43: 2426-8
97. Zhou Z, Ng PC, Very DL, Allard WJ, Yeung KK. Technicon Immuno-1 PSA assay measures both free and alpha 1-antichymotrypsin complexed prostate specific antigen on an equimolar basis. J Clin Lab Anal 1996; 10: 155-9
98. Blase AB, Sokoloff RL, Smith KM. Free PSA methods compared by assaying samples with defined PSA ratios. Clin Chem 1997; 43: 843-5
99. Cheli CD, Marcus M, Levine J, Zhou M, Anderson PH, Bankson DD, et al. Variations in the quantitation of prostate specific antigen in reference materials: differences in commercial immunoassays. Clin Chem 1998; 44: 1551-3
100. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Schnall M, Tomaszewski JE, et al. A multivariate analysis of clinical and pathological factors that predict for prostate specific antigen failure after radical prostatectomy for prostate cancer. J Urol 1995; 154: 131-8
101. Stein A, de Kernion JB, Smith RB, Dorey F, Patel H. Prostate specific antigen levels after radical prostatectomy in patients with organ-confined and locally extensive prostate cancer. J Urol 1992; 147: 942-7
102. Yu H, Diamandis EP, Wong PY, Nam R, Trachtenberg J. Detection of prostate cancer relapse with prostate specific antigen monitoring at levels of 0-001 to 0.1 μg/L. J Urol 1997; 157: 913-8
103. Prestigiacomo AF, Stamey TA. A comparison of 4 ultrasensitive prostate specific antigen assays for early detection of residual cancer after radical prostatectomy. J Urol 1994; 152: 1515-9
104. World Health Organization. WHO Report 1999. WHO Expert Committee on Biological Standardisation. Geneva: World Health Organization, 1999
105. Rafferly B, Rigsby P, Rose M, Stanley T, Gaines Das R. Reference reagents for Prostate Specific Antigen (PSA): Establishment of the First International Standards for free PSA and PSA (90:10). Clin Chem 2000; 46: 1310-7
106. Parfait R, Mast W-P, Volk M, Lynch S, Vanderkerckhove J, Carayon P, et al. Preparation of a certified prostate specific antigen (PSA) reference material (CRM 613). European Commission, 1999; EUR 18900
107. Zhou Z, Chen Y, Allard WJ, Yeung KK. Bayer Immuno-1 c-PSA assay measures PSA ACT and PSA AAT. Clin Chem 1999; 45: A118-9
108. Myrtle JF, Klimley P, Ivor L, Bruni J. Clinical utility of prostate specific antigen (PSA) in the management of prostate cancer. In: Advances in Cancer Diagnostics. San Diego: Hybritech Inc. 1986
109. Catalona WJ, Richie JP, Ahmann FR, Hudson MA, Scardino PT, Flanigan RC, et al. Comparison of DRE and serum PSA in the early detection of prostate carcinoma: results of a multicenter clinical trial of 6630 men. J Urol 1994; 151: 1283-90
110. Dalkin BL, Ahmann FR, Kopp JB. Prostate specific antigen levels in men older than 50 years without clinical evidence of prostatic carcinoma. J Urol 1993; 150: 1837-9
111. Oesterling JE, Jacobsen SJ, Chute GG, Guess HA, Girman CJ, Panser EA, et al. Serum prostate specific antigen in a community-based population of healthy men: Establishment of age-specific reference ranges. JAMA 1993; 270: 860-4
112. Parkes C, Wald NJ, Murphy P, George L, Watt HC, Kirby R, et al. Prospective observational study to assess the value of prostate specific antigen as a screening test for prostate cancer. BMJ 1995; 311: 1340-3
113. Morgan TO, Jacobsen SJ, McCarthy WF. Age-specific reference ranges for serum prostate specific antigen in black men. N Engl J Med 1996; 335: 304-10
114. Oesterling JE, Jacobsen SJ, Klee GG. Pettersson K, Piironen T, Abrahamsson PA, et al. Free, complexed and total serum prostate specific antigen: the establishment of appropriate reference ranges for their concentration and ratios. J Urol 1995; 154: 1090-5
115. Leung HY, Lai LC, Day J, Thompson J, Neal DE, Hamdy FC. Serum free prostate specific antigen in the diagnosis of prostate cancer. Brit J Urol 1997; 80: 256-9
116. Honda SA, Goldstein AP, Morita AP, Sugiyama C, Cody L, Rios CN, et al. Prostate specific antigen concentrations in serum in acute illnesses. Clin Chem 1996; 42: 1785-8
117. Lilja H, Christensson A, Dahlen U, Matikainen MT, Nilsson O, Pettersson K, et al. Prostate specific antigen (PSA) in human serum occurs predominately in complex with α1-antichymotrypsin. Clin Chem 1991; 37: 1618-25
118. Partin AW, Catalona WJ, Southwick PC, Subong EN, Gasior GH, Chan DW. Analysis of percent free prostate specific antigen (PSA) for prostate cancer detection: influence of total PSA, prostate volume and age. Urology 1996; 48: 55-61
119. Collins GN, Alexandrou K, Wynn-Davies A, Mobley S, O'Reilly PH. Free prostate specific antigen 'in the field': a useful adjunct to standard clinical practice. BJU International 1999; 83: 1000-2
120. Morote J, Encabo G, Lopez MA, de Torres IM. The free-total serum prostate specific antigen ratio as a predictor of the pathological features of prostate cancer. BJU International 1999; 83: 1003-6
121. Filella X, Alcover J. Molina R, Gimenez N, Rodriguez A. Jo J, et al. Clinical usefulness of the free PSA fraction as an indicator of prostate cancer. Int J Cancer 1995; 63: 780-4
122. Lodding P, Aus G, Bergdahl S, Frosing R, Lilja H, Pihl CG, et al. Characteristics of screening detected prostate cancer in men 50 to 66 years old with 3 to 4 ng/mL prostate specific antigen. J Urol 1998; 159: 899-903
123. Virtanen A, Goinari M, Kranse R, Stenman UH. Estimation of prostate cancer probability by logistic regression: free and total prostate specific antigen, digital rectal examination, and heredity are significant variables. Clin Chem 1999; 45: 987-94
124. Catalona WJ, Smith DS, Wolfert R, Wang TJ, Rittenhouse HG, Ratliff TL, et al. Evaluation of percentage of free serum prostate specific antigen to improve prostate cancer screening. JAMA 1995; 274: 1214-20
125. Pearson JD, Luderer AA, Metter FJ, Parlin AW, Chan DW, Fozard JL, et al. Longitudinal analysis of serial measurements of free and total PSA among men with and without prostate cancer. Urology 1996; 48(Suppl): 4-9
126. Patel D, White PA, Milford Ward A. The predictive value of PSA index. A comparative evaluation of six commercial assays for total and free PSA. BJU International 2000; 85: 1-4
127. Pannek J, Subong EN, Jones KA, Marschke PL, Epstein JL, Chan DW, et al. The role of free to total prostatic specific antigen ratio in the prediction of final pathologic stage for men with clinically localised prostate cancer. Urologu 1996; 48(Suppl): 51 4
128. Pannek J, Rittenhouse HG, Chan DW, Epstein JL, Walsh PC, Partin AW. The use of percent free prostatic specific antigen for staging clinically localised prostate cancer. J Urol 1998; 159: 1238-42
129. Jung K, Elgeti U, Lein M, Brux B, Sinha P, Rudolph B, et al. Ratio of free or complexed prostate specific antigen (PSA) to total PSA: which ratio improves differentiation between benign prostatic hyperplasia and prostate cancer? Clin Chem 2000; 46: 55-62
130. Allard WJ, Cheli CD, Neaman IE, Goldblatt J, Morris DL, Smith C, et al. Complexed PSA and free to total PSA ratio provide equivalent specificity in the detection of prostate cancer but would save biopsies in different patient populations. Clin Chem 1999; 45: A106
131. Brawer MK, Meyer GE, Letran JL, Bankson ER, Moriss DL, Yeung KK, et al. Measurement of complexed PSA improves specificity for early detection of prostate cancer. Urology 1998; 52: 372-8
132. Rittenhonse HG, Chan DW. Can complexed PSA be used as a single test for detecting prostate cancer? Urology 1999; 54: 4-5
133. Terris MK, Stamey TA. Determination of prostate volume by transrectal ultrasound. J Urol 1991; 145: 984-7
134. Seaman E, Whang IS, Olsson C, Catz A, Cooner WH, Benson MC. PSA density (PSAD). Role in patient evaluation and management. Urol Clin N Amer 1993; 20: 653-63
135. Partin AW, Oesterling JE. The clinical usefulness of prostate specific antigen: Update 1994. J Urol 1994; 152: 1358-68
136. Barak M, Cohen M, Mecz Y, Stein A, Rashkovitzki R, Laver B, et al. The additional value of free prostate specific antigen to the battery of age-dependent prostate specific antigen, prostate specific antigen density and velocity. Eur J Clin Chem Clin Biochem 1997; 35: 475-81
137. Carter HB, Pearson JD, Metter EJ, Brant LJ, Chan DW, Andres R, et al. Longitudinal evaluation of prostate specific antigen levels in men with and without prostate disease. JAMA 1992; 267: 2215-20
138. Bachem MG, Brandle E, Hautmann O. Hautmann RE, Steinbach G, Grunert A. Determina- tion of serum half-life time of free and total prostate specific antigen in patients after radical prostatectomy. Clin Chem 1999; 45: A106
139. Oesterling JR, Chan DW, Epstein JL, Kimball AW, Bruzek DJ, Rock RC, et al. Prostate specific antigen in the preoperative and postoperative evaluation of localised prostate cancer treated by radical prostatectomy. J Urol 1988; 139: 766-72
140. Richardson TD, Wojno K, Liang LW, Giacherio DA, England BG, Henlicks WH, et al. Half-life determinations of serum free prostate specific antigen following radical prostatectomy. Urology 1996; 48(Suppl): 40-4
141. Yu H, Diamandis EP, Prestigiacomo AF, Stamey TA. Ultrasensitive assay of prostate specific antigen used for the early detection of prostate cancer relapse and estimate of tumor doubling time after radical prostatectomy. Clin Chem 1995; 41: 430-4
142. Vessella RL. Trends in immunoassays of prostate specific antigen: serum complexes and ultrasensitivity. Clin Chem 1993; 39: 2035-9
143. Schmid HP, McNeal JE, Stamey TA. Observations on the doubling time of prostate cancer. Cancer 1993; 71: 2031-40
144. Pannek J, Marks LS, Pearson JD, Rittenhouse HG, Chan DW, Sherry ED, et al. Influence of finasteride on free and total serum prostate specific antigen levels in men with benign prostatic hyperplasia. J Urol 1998; 159: 449-53
145. Bossens MM, Van Straalen JP, Dc Reijke TM, Kurth TH, Sanders GT. Kinetics of prostate specific antigen after manipulation of the prostate. Eur J Cancer 1995; 31A: 682-5
146. Oesterling JE, Rice DC, Olenski WJ, Bergstralh EJ, Effect of cystoscopy, prostate biopsy and transurethral resection of the prostate on serum prostate specific antigen concentration. Urology 1993; 42: 276-82
147. Zisman A, Soffer Y, Siegel Y, Paz A, Lindner A. Post-ejaculation prostate specific antigen levels. Eur Urol 1997; 32: 54-7
148. Pettersson K, Piironen T, Seppalla M, Liukkonen L, Christensson A, Matikainen M-T, et al. Free and complexed prostate specific antigen (PSA): in vitro stability, epitope map, and development of immunofluorometric assays for specific and sensitive detection of free PSA and PSA-α1-antichymotrypsin complex. Clin Chem 1995; 41: 1480-8
149. Sokoll LJ, Briedenstein C, Bruzek DJ, Dunn W, Jarrar P, Kidwell W, et al. Reactivity of free and complexed forms of PSA: examination of CAP survey discrepancies. Clin Chem 1999; 45: A117
150. Lee M, White PA, Milford Ward A. Fifteen PSA assays. MDA Evaluation Report, 1998, MDA/98/12
151. Patel D, Milford Ward A, White PA. Five free:total PSA kits. MDA Evaluation Report, 2000, MDA2000/40